Trial Profile
Cerebrovascular Reactivity Assessed With Functional Near-infrared Spectroscopy as a Biomarker of Traumatic Microvascular Injury After Moderate-severe Traumatic Brain Injury
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Sildenafil (Primary)
- Indications Brain injuries
- Focus Therapeutic Use
- 10 Oct 2022 Status changed from recruiting to discontinued.
- 18 Sep 2020 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 18 Sep 2020 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2026.